top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 9 minutes ago
  • 1 min read

16/02/2026















Roche announced positive Phase 3 results for Gazyva/Gazyvaro in primary membranous nephropathy (Ref)


Roche announced positive results from the Phase 3 MAJESTY/ NCT04629248 study which evaluated the efficacy and safety of Gazyva/Gazyvaro (obinutuzumab; anti-CD20) in patients with primary membranous nephropathy


  • The study met its primary endpoint of complete remission at two years, with a statistically significantly higher number of patients achieving complete remission at two years with Gazyva than with tacrolimus


  • The safety profile was consistent with the well-characterized profile of Gazyva and no new safety signals were identified


  • The data are planned to be presented at an upcoming medical meeting and shared with health authorities including the US FDA and EMA

bottom of page